Expansion Therapeutics
Small molecule therapeutics that target RNA to treat expansion repeat disorders
- Sector
- Biotech
- Headquarters
- Jupiter, FL
- Founded
- 2016
- Latest Form D
- $48M, Oct 2021
- Total capital
- $73.6M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $73.6M
- 3 Form D · last Oct 2021
- 60 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 2 pending · first 2021
- Rank in peer group#481 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$48M
- Private capital raisedForm D · SEC · 2nd filing$25.3M
- Private capital raisedForm D · SEC · 1st filing$250K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#481 · top 33%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Matthew DisneyResearcherDirectorLinked by 1 patent
- Andy Phillips, Ph.D.DirectorNamed in SEC Form D filings
- Beth Seidenberg, M.D.DirectorNamed in SEC Form D filings
- Campbell Murray, M.B.B.S., M.B.A.DirectorNamed in SEC Form D filings
- Jason HaflerDirectorNamed in SEC Form D filings
- Jason Hafler, Ph.D.DirectorNamed in SEC Form D filings
Show all 16 people
- Kevin ForrestExecutive Officer, DirectorNamed in SEC Form D filings
- Kevin Forrest, Ph.D.Executive Officer, DirectorNamed in SEC Form D filings
- Laura Tadvalkar, Ph.D.DirectorNamed in SEC Form D filings
- Matthew Disney, Ph.D.DirectorNamed in SEC Form D filings
- Paul StoneExecutive OfficerNamed in SEC Form D filings
- Renato Skerlj, Ph.D.Executive Officer, DirectorNamed in SEC Form D filings
- Scott RocklageExecutive Officer, DirectorNamed in SEC Form D filings
- Scott Rocklage, Ph.D.DirectorNamed in SEC Form D filings
- Yujiro HataDirectorNamed in SEC Form D filings
- Yujiro Hata, M.B.A.DirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 3- GrantedBis-benzimidazole Compounds And Methods Of Using The SameUSPTOUS 10,961,202
- PendingBis-benzimdazole Compounds And Methods Of Using SameUSPTOApplication PCTUS2018061442
- PendingBis-benzimidazole Compounds And Methods Of Using The SameUSPTOApplication 62587606
Related companies, and why
- Larimar TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Nocion Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Comanche BiopharmaSimilar federal contract value in Biotech · null in contracts
- SepternaSimilar federal contract value in Biotech · null in contracts
- Blueprint MedicinesSimilar federal contract value in Biotech · null in contracts
- Spark Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .